The condition was first described in Japan in the 1990s and named after the takotsubo, an octopus trap whose bulbous shape resembles the ballooned left ventricle seen on imaging in affected patients. Classic teaching held that the syndrome followed intense emotional distress, most often in older women, and that the heart would bounce back within days or weeks. Subsequent registries have steadily eroded that picture. Outcomes comparable to matched cohorts of patients with ST-segment elevation myocardial infarction have been reported, and roughly one in three cases is now known to be provoked not by grief or shock but by a physical trigger such as surgery, infection, or trauma. The new analysis adds a detailed comparison of trigger categories to this evolving landscape.

The pathophysiology of takotsubo syndrome remains incompletely understood, but the leading hypothesis centers on a catecholamine storm. Circulating epinephrine and norepinephrine, released in response to overwhelming stress, are thought to stun the heart muscle through a combination of direct toxicity, microvascular dysfunction, adrenoreceptor modulation, and intracellular calcium overload in cardiomyocytes. Animal models have reproduced takotsubo-like dysfunction by injecting epinephrine, and patients with the syndrome show elevated norepinephrine concentrations in the coronary sinus, suggesting local cardiac release as well. More recent work has shifted attention upstream, to the brain–heart axis: structural and functional alterations in central autonomic regions such as the amygdala, insula, and limbic network have been documented in patients with the syndrome, implicating the neural circuitry of stress processing itself.

Against this backdrop, the German team set out to answer three questions. First, does acute brain pathology drive cardiac dysfunction differently than other physical or emotional stressors? Second, how quickly and completely does cardiac function recover in the short term? Third, can clinicians better identify the patients most likely to deteriorate critically during hospitalization? To do so, they classified each patient’s trigger as acute neurologic, physical, emotional, or unidentifiable, and followed outcomes through discharge.

The trigger distribution was revealing. Among the 593 patients who could be categorized, physical triggers accounted for 38 percent, emotional triggers for 16 percent, and acute neurologic emergencies for 6 percent, while no trigger could be identified in 40 percent of cases. Within the neurologic group, epileptic seizures were the most common precipitant at 49 percent, followed by ischemic stroke at 29 percent. The cohort itself matched the classic profile in many respects: median age was 72 years, 88 percent were women, and chest pain and dyspnea dominated the presenting symptoms. Median left ventricular ejection fraction at admission was 40 percent, and the overwhelming majority of patients — 92 percent — showed the apical ballooning pattern considered typical of the disease.

The risk gradient across triggers was stark. Using generalized estimating equations adjusted for age, sex, hypertension, coronary artery disease, diabetes, and chronic kidney disease, the researchers estimated the marginal risk of a composite cardiac endpoint — new-onset atrial fibrillation, ventricular tachycardia or fibrillation, pulmonary edema, cardiogenic shock, or in-hospital death. Patients with neurologic triggers faced a 48 percent risk, those with physical triggers 38 percent, and those with emotional triggers only 13 percent. Compared with the neurologic group, the odds ratio for the composite endpoint was 0.16 for emotional triggers and 0.40 for cases with no identifiable trigger, while physical triggers did not differ significantly. A sensitivity analysis that removed in-hospital death from the endpoint produced a similar pattern, suggesting the findings were not simply an artifact of the triggering illness itself being lethal.

Recovery, the study found, is far from uniform. Only 32 percent of patients with available imaging showed reversal of their wall motion abnormalities by discharge, and 42 percent recovered normal systolic function. In multivariable mixed-effects models, patients with atypical, nonapical forms of the syndrome had markedly better odds of wall motion recovery, with an odds ratio of 2.70, and higher admission ejection fraction independently predicted recovery as well. Older patients fared worse on the systolic front, with each increment in age associated with lower odds of ejection fraction normalization by discharge (odds ratio 0.67). Patients with neurologic triggers showed a trend toward poorer wall motion recovery that did not reach statistical significance. The authors note that these figures likely underestimate eventual recovery, since observation ended at discharge, but the message is clear: the notion of quick, complete myocardial healing does not apply to everyone.

Perhaps the most clinically actionable findings concern who deteriorates. In a model of critical in-hospital course — defined as need for inotropic support, mechanical ventilation, cardiogenic shock, mechanical circulatory support, or death — lower admission ejection fraction emerged as the dominant predictor, with an odds ratio of 0.44. Younger age paradoxically predicted worse outcomes (odds ratio 0.76), as did male sex (odds ratio 1.96). When triggers were added to the model, acute neurologic emergencies tripled the odds of a critical course (odds ratio 3.10), and physical triggers nearly doubled them (odds ratio 2.08). The authors propose that a young, otherwise healthy heart may require a far more violent sympathetic surge to fail in the first place, and that same intensity of stimulation then drives the severity of the hospital course — a hypothesis consistent with prior reports from the international InterTAK and German GEIST registries.

The neurologic findings carry particular weight for the emerging field of neurocardiology. Acute brain injury — whether ischemic stroke, subarachnoid hemorrhage, or status epilepticus — is known to provoke massive catecholamine release and cardiac changes that can be difficult to distinguish from takotsubo syndrome, a phenomenon sometimes labeled neurogenic stunned myocardium. Damage to central autonomic structures, heightened sympathetic tone, and catecholamine-driven modulation of cardiac ion channels are thought to underlie the arrhythmias seen in these patients, and new-onset atrial fibrillation was indeed most frequent in the neurologic trigger group at 11 percent. The authors caution, however, that causality cannot be established in a retrospective design, and that in some cases subclinical atrial fibrillation may even have caused the stroke that then appeared to trigger the syndrome.

The study has limitations the authors acknowledge candidly. All patients were treated at tertiary care centers, which may overrepresent severe cases; missing data were addressed through multiple imputation with sensitivity analyses; and follow-up ended at discharge, precluding assessment of longer-term recovery. Nevertheless, the overall conclusion lands with force. Takotsubo syndrome is not a uniformly reversible stress response, and the old caricature of a benign condition affecting grieving grandmothers no longer serves patients or clinicians. Younger men with severely depressed ejection fractions, particularly when the episode follows a stroke, seizure, infection, or surgery, constitute a high-risk phenotype that warrants intensive monitoring, careful hemodynamic support — including consideration of mechanical circulatory support in cardiogenic shock, since inotropes are generally discouraged — and structured follow-up after discharge. As the authors put it in their conclusion, early risk stratification and awareness of high-risk features are essential, because the heart that appears to be merely stunned may, in a substantial minority of patients, be genuinely endangered.

Subject of Research: Trigger-dependent risk, recovery, and critical course in takotsubo syndrome

Article Title: New insights into takotsubo syndrome: results from a multicenter cohort

Article References: Lanz, H., Cekaj, E., Bacmeister, L., Jung, C., Muli, S., Hoffmann, S., Schmid, M., Galdos-Bejar, M., Hoyer, D., Crusius, L., Mangner, N., Reinhardt, L., Yahsaly, L., Michel, L., Pfeiffer, V., Salem, M., Rangel, R. H., Terporten, J., Heindl, F., … Lüsebrink, E. (2026). New insights into takotsubo syndrome: results from a multicenter cohort. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03037-8

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03037-8

Keywords: takotsubo syndrome, broken heart syndrome, neurologic triggers, catecholamines, brain-heart axis, cardiogenic shock, left ventricular recovery, wall motion abnormalities, stress cardiomyopathy, multicenter cohort, risk stratification, cardiology

The technique at the center of the study, CT-derived fractional flow reserve or CT-FFR, deserves a moment of explanation because it is doing the heavy scientific lifting here. Fractional flow reserve is classically measured with a pressure wire threaded into a coronary artery during invasive catheterization; it expresses the ratio of blood pressure distal to a stenosis to the pressure available in the aorta, with values below 0.80 generally signaling ischemia that warrants stenting. CT-FFR replicates this measurement computationally. Software ingests the geometry of the coronary tree extracted from a coronary CT angiogram, models the physics of blood flow through it, and estimates the pressure drop across each lesion without ever entering the patient’s body. That means researchers can, in principle, measure the functional significance of coronary narrowings repeatedly over time, at low risk and low cost, which is exactly what made the present longitudinal design feasible.

The investigators took a retrospective look at patients who had undergone TAVR for aortic stenosis and who also happened to have coronary CT angiography both before the procedure and at least six months afterward. That second scan is not routine practice; it was obtained on the basis of individualized clinical decisions, which introduces some selection considerations the authors acknowledge. From the available records, 62 patients made it into the final analysis, contributing 112 coronary arteries for paired evaluation. Every included patient had at least one coronary stenosis of moderate severity, in the 30 to 90 percent range, at baseline. The median interval between the pre-procedure scan and the follow-up scan was 363 days, so the team was effectively comparing the coronary circulation one year apart, straddling the valve replacement.

The headline finding is counterintuitive: after the aortic valve was fixed, CT-FFR values across the studied arteries went down, not up. Across all vessels, the mean CT-FFR fell from 0.84 before TAVR to 0.82 afterward, a small but highly statistically significant decline. When the arteries were analyzed by vessel, the pattern became more textured. The right coronary artery dropped from 0.89 to 0.83, and the left circumflex artery fell from 0.82 to 0.79, both statistically significant changes. The left anterior descending artery, the largest and most clinically scrutinized coronary vessel, showed no significant change, edging from 0.84 to 0.85. None of these post-TAVR values crossed the conventional 0.80 ischemic threshold on average, but the direction of travel was consistent enough to demand an explanation.

The obvious first suspect was plaque progression. If atherosclerosis had advanced during the follow-up year, the pressure drop across lesions would increase and FFR would fall. So the researchers systematically compared qualitative plaque features, such as the presence of low-attenuation cores, spotty calcium and the napkin-ring sign, along with quantitative metrics like plaque volume and stenosis percentage, between the baseline and follow-up scans. The result was a null finding of real scientific value: no significant differences emerged in any qualitative or quantitative plaque characteristic. The atherosclerotic burden, as seen by CT, was essentially frozen in place. And when the team formally tested the relationship, they found no correlation between changes in CT-FFR and changes in plaque measurements, effectively ruling out plaque dynamics as the driver of the hemodynamic shift.

That leaves hemodynamics itself, and here the study offers a compelling clue. The left ventricular mass index, a measure of the thickness and bulk of the heart’s main pumping chamber, decreased significantly after TAVR, confirming the well-documented phenomenon of reverse remodeling: once the pressure overload of aortic stenosis is relieved, the hypertrophied muscle begins to shrink back toward normal. Intriguingly, the magnitude of LV mass regression showed a trend toward correlation with the change in CT-FFR, with a correlation coefficient of -0.183 and a P value of 0.054, just shy of conventional significance. The authors interpret this as evidence that the falling FFR values primarily reflect improved hemodynamics secondary to relief of the valve obstruction and ventricular remodeling, rather than any worsening of the coronary lesions themselves.

The physiology behind that interpretation is worth unpacking. Fractional flow reserve is not a fixed property of a stenosis; it depends on the flow of blood racing through the narrowed segment during maximal hyperemia. When the aortic valve is replaced, downstream resistance falls, the ventricle generates pressure more efficiently, and coronary flow patterns change in complex ways. Microvascular function, which is often abnormal in aortic stenosis, also evolves during recovery. Any of these shifts can alter the pressure gradient across a coronary lesion independent of its anatomy. In other words, the same anatomical narrowing can be functionally different in a remodeled heart, and the study’s data suggest that is precisely what CT-FFR is capturing in these patients.

For clinicians, the implications cut in two directions. On one hand, the findings are reassuring: a modest post-TAVR decline in CT-FFR, in a stable patient, does not appear to signal aggressive plaque growth and may simply be a byproduct of a heart recalibrating to its new pressure environment. On the other hand, the results are a caution against interpreting serial CT-FFR values in TAVR patients the way one would in ordinary stable chest pain populations. The reference frame changes after valve replacement, and a drop of a few hundredths in FFR may carry a very different meaning in a ventricle that is actively unloading and remodeling. The authors are careful to note that their conclusions apply primarily to clinically stable patients, and that follow-up CT angiography in this cohort was performed on individualized clinical grounds rather than as a standardized protocol.

The study also carries honest limitations that shape how far its message travels. It was retrospective and observational, with a modest sample of 62 patients, and the decision to obtain post-TAVR CCTA was not uniform, raising the possibility of selection effects. The follow-up window, while a median of nearly a year, captures only one snapshot of what is likely a longer remodeling trajectory. Still, the core contribution stands: this is one of the clearest demonstrations that after TAVR, coronary functional measurements and coronary anatomy can decouple, with FFR drifting downward while plaque burden holds steady. As CT-FFR becomes more widely adopted and as TAVR expands to younger and lower-risk patients, understanding this post-procedural hemodynamic evolution will matter for deciding which lesions truly need stenting and which are simply adapting to a heart that has been set free. The Shenyang team’s data suggest that, at least in the first year after valve replacement, the arteries themselves are not the story; the recovering ventricle is.

Subject of Research: Changes in CT-derived coronary fractional flow reserve and plaque characteristics after transcatheter aortic valve replacement

Article Title: Coronary hemodynamic and plaque changes following transcatheter aortic valve replacement

Article References: Fang, Y., An, C., Sun, Y., Wang, B., Wang, G., Liang, Z., Li, Y., Xu, K., & Han, Y. (2026). Coronary hemodynamic and plaque changes following transcatheter aortic valve replacement. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02763-9

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02763-9

Keywords: TAVR, aortic stenosis, CT-FFR, coronary CT angiography, fractional flow reserve, coronary plaque, left ventricular mass, reverse remodeling, cardiology, medical imaging, hemodynamics, BMC Medical Imaging

The core of the proposed system is a hybrid architecture that combines a fully fine-tuned ResNet50 convolutional neural network with a 10-qubit variational quantum circuit. In this design, the ResNet50 backbone serves as the feature extractor, processing the input ECG images to identify relevant patterns. These features are then passed to the quantum circuit, which acts as a classifier. This approach leverages the strengths of classical deep learning for high-dimensional data processing while attempting to exploit the potential computational benefits of quantum superposition and entanglement for the final decision-making step. The authors aimed to determine if this hybrid structure could maintain high classification performance even when the input images are downsampled, a scenario that might occur in resource-constrained environments or for rapid screening applications.

To rigorously assess the algorithm’s performance, the researchers utilized a dataset of 24,799 held-out ECG images. They evaluated the model at five controlled content resolutions: 80, 112, 160, 224, and 320 pixels. This multi-resolution approach is essential because it tests the robustness of the model against varying levels of spatial information. By comparing the hybrid quantum algorithm against a conventional ResNet50 classifier and a closely parameter-matched classical 10-dimensional bottleneck, the study isolates the specific contribution of the quantum component. The classical bottleneck serves as a fair baseline, ensuring that any observed differences in performance are attributable to the quantum processing rather than simply the architecture’s capacity or the number of parameters involved.

At the highest resolutions of 224 and 320 pixels, all three approaches reached ceiling-level classification performance. This indicates that when sufficient spatial detail is available, the choice of classifier—whether classical or hybrid quantum—has a minimal impact on the final accuracy. The models were able to extract enough information from the high-resolution images to distinguish between the six arrhythmia classes with high confidence. However, the study found that differences between the architectures became more apparent as the spatial information was reduced, highlighting the potential niche for quantum-enhanced processing in scenarios where data fidelity is compromised.

At a resolution of 112 pixels, the hybrid quantum algorithm demonstrated a mean accuracy of 0.9690 with a standard deviation of 0.0124 across three independent training seeds. In comparison, the conventional ResNet50 achieved a mean accuracy of 0.9396 with a standard deviation of 0.0044, while the classical bottleneck recorded a mean accuracy of 0.9580 with a standard deviation of 0.0354. Although the hybrid algorithm achieved the highest mean accuracy, the corresponding macro-F1 scores revealed a more nuanced picture. The hybrid algorithm scored 0.8638 ± 0.0417, the ResNet50 scored 0.8235 ± 0.0062, and the classical bottleneck scored 0.8783 ± 0.1033. These results suggest that while the hybrid model may offer higher accuracy, its performance can be less consistent across different training initializations compared to the classical counterparts.

The variability in performance across training seeds is a significant finding, indicating a sensitivity to optimization randomness in the hybrid quantum architecture. At 160 pixels, the architectures approached ceiling performance, suggesting that the quantum pathway does not provide a consistent classification advantage across all resolutions. At the lowest tested resolution of 80 pixels, the hybrid algorithm and the standard ResNet50 showed comparable classification behavior, with neither demonstrating a clear superiority. This implies that the benefits of the quantum component are most relevant in the intermediate range of spatial information reduction, where classical models begin to struggle with the loss of detail but have not yet reached the point of complete failure.

The study underscores the importance of considering both accuracy and stability when evaluating new machine learning models for medical applications. While a higher mean accuracy is desirable, a model that is highly sensitive to random initialization may pose challenges for reproducibility and clinical deployment. The classical bottleneck, despite having a lower mean accuracy than the hybrid model at 112 pixels, exhibited a much lower standard deviation in its macro-F1 score, suggesting a more stable performance profile. This trade-off between peak performance and consistency is a critical consideration for healthcare providers who require reliable diagnostic tools that perform predictably across different patient populations and data conditions.

It is important to note that the results reflect image-level benchmark performance without patient identifiers or external validation. The authors emphasize that broader generalizability requires patient-independent and external validation studies. In clinical settings, the ability of a model to generalize across different patients, demographics, and hospital environments is paramount. The current study provides a strong foundation for understanding the technical capabilities of the hybrid quantum algorithm, but further research is needed to confirm its utility in real-world clinical workflows. The lack of external validation means that the findings should be interpreted as a proof of concept rather than a definitive clinical recommendation.

This research contributes to the growing body of literature on quantum machine learning in healthcare, offering a detailed analysis of the conditions under which quantum components may be beneficial. By systematically varying the input resolution and comparing against well-established classical baselines, the authors provide valuable insights into the practical limitations and potential advantages of hybrid quantum-classical architectures. As quantum hardware continues to advance and become more accessible, such studies will be crucial for guiding the integration of quantum technologies into medical imaging and signal processing pipelines. The work highlights the need for careful benchmarking and the recognition that quantum advantage is not universal but context-dependent.

The implications of this study extend beyond arrhythmia classification to other areas of medical imaging where data resolution may vary. The hybrid approach could potentially be adapted for other diagnostic tasks, provided that the specific conditions for quantum advantage are met. Researchers and clinicians interested in quantum-enhanced diagnostics should consider the balance between computational complexity, data resolution, and model stability when designing their systems. The findings from this study serve as a cautionary tale against assuming that quantum computing will automatically outperform classical methods in all scenarios, while also demonstrating that there are specific niches where hybrid approaches may offer competitive performance. Future work should focus on expanding the dataset, incorporating external validation, and exploring more complex quantum circuits to further elucidate the potential of quantum machine learning in cardiology.

Subject of Research: Hybrid quantum algorithm performance in multi-resolution ECG arrhythmia classification

Article Title: A hybrid quantum algorithm for multi-resolution arrhythmia classification

Article References: Ramkhelawan, M. Y., Wibowo, S., Grandhi, S., & Mandala, S. (2026). A hybrid quantum algorithm for multi-resolution arrhythmia classification. Scientific Reports. https://doi.org/10.1038/s41598-026-76787-0

Image Credits: AI Generated

DOI: 10.1038/s41598-026-76787-0

Keywords: quantum computing, ECG analysis, arrhythmia detection, deep learning, medical imaging, hybrid algorithms, ResNet50, cardiology, machine learning, signal processing, hybrid, quantum

Now a team of researchers at Anhui Science and Technology University in China has developed an artificial intelligence architecture that dramatically improves how well algorithms can identify these abnormal beats from very short recordings. The system, called GCTRNet, was described in a study published in Frontiers in Physiology, and its central innovation is surprisingly elegant: rather than adding new encoders or exotic signal transforms, it teaches the network to look back at the whole segment it just analyzed and refine its own internal notes before making a final decision.

The difficulty stems from a fundamental data problem. A two-second ECG window contains only a handful of heart cycles, and the electrical signature of a PVC varies enormously from patient to patient. The widened QRS complex, altered amplitude, unusual slopes, and post-beat waveform changes that signal a premature ventricular contraction in one person may look quite different in another. Earlier generations of automated detectors relied on hand-crafted features, such as RR intervals, QRS duration, and wavelet coefficients, fed into classifiers like support vector machines or random forests. These approaches worked reasonably well but depended heavily on careful signal preprocessing, accurate localization of fiducial points, and the judgment of domain experts. Crucially, separating feature extraction from classification prevented the entire pipeline from being optimized as a unified whole.

Deep learning changed the paradigm by learning representations directly from raw or minimally processed signals. Convolutional neural networks excel at capturing local waveform shapes, while recurrent architectures such as long short-term memory networks, and their bidirectional variants known as BLSTMs, track temporal dependencies that unfold across the recording. Combining the two has become standard practice for arrhythmia classification. Yet the researchers identified a subtle gap in how these hybrid models typically work: the hidden states produced by a BLSTM are usually pooled directly into a single summary vector, meaning that segment-level context is computed only after temporal encoding and never fed back into the sequence itself. Information about how the whole segment relates to each individual moment gets lost at exactly the wrong point in the pipeline.

GCTRNet closes that gap with a module the authors call Global Context-Gated Temporal Refinement, or GCTR. The architecture begins with a multi-scale convolutional encoder that processes the two-second, 500-sample ECG segment through three parallel branches with kernel sizes of seven, fifteen, and thirty-one samples, corresponding to receptive fields of roughly twenty-eight, sixty, and one hundred twenty-four milliseconds at a sampling rate of 250 hertz. These complementary scales capture sharp QRS transitions as well as broader peri-beat waveform structure. The concatenated features are fused and passed to a BLSTM with 128 hidden units in each direction, producing a sequence of 256-dimensional hidden states across 250 temporal positions.

Then comes the refinement step that gives the network its name. GCTR first summarizes the entire hidden-state sequence into a single context vector, projects it through a learnable nonlinear transformation, and broadcasts it back across every temporal position. An adaptive gate, built from a sigmoid function, decides at each moment how much of this global context should be blended into the local hidden state. The gated update is applied as a residual, scaled by a learnable coefficient that was initialized at a tiny value of 0.01, allowing the model to start close to the original BLSTM representation and gradually learn how strongly to trust the contextual feedback. Layer normalization then stabilizes the output before temporal mean pooling and a final binary classifier deliver the verdict: PVC or normal beat.

The team evaluated the system on the MIT-BIH Arrhythmia Database, a benchmark collection of forty-eight Holter recordings sampled at 360 hertz, using a strictly patient-independent partition in which no recording or subject appeared in more than one dataset split. After resampling to 250 hertz and denoising with a Daubechies-6 wavelet transform, the researchers extracted 81,358 two-second segments, of which 6,899 were PVCs. The frozen seed-2024 model achieved an accuracy of 99.65 percent, a sensitivity of 96.82 percent, and a specificity of 99.91 percent on the held-out test set of 13,300 segments. Across three random seeds, GCTRNet outperformed matched BLSTM-based comparison models, including variants with squeeze-and-excitation and temporal attention mechanisms, by margins of 2.16 to 6.00 percentage points in mean F1-score, all while using only about 402,714 parameters, roughly one-tenth of the 3.84 million parameters in a ResNet1D baseline.

The most striking result, however, came from external validation. The researchers locked the trained model and applied it, without any retraining or threshold adjustment, to a predefined subset of the China Physiological Signal Challenge 2021 dataset comprising 210 recordings from 105 patients, where PVCs made up only 2.07 percent of segments. Under this cross-database domain shift, GCTRNet achieved 97.83 percent accuracy, 84.75 percent sensitivity, and an area under the precision-recall curve of 80.49 percent, the best sensitivity, F1-score, and AUPRC among all frozen models tested. Notably, the ResNet1D baseline, which had posted the best internal numbers, collapsed on the external data, producing over 105,000 false positives and a precision of just 5.98 percent. The reversal underscores a lesson the field keeps relearning: strong performance on a familiar benchmark guarantees little about real-world transfer.

Interpretability analyses added texture to the story. In the 256-dimensional feature space, the silhouette coefficient improved from 0.423 to 0.526 after GCTR refinement, while the Davies-Bouldin index fell from 0.744 to 0.680, indicating better class separation. Integrated Gradients attribution showed that GCTRNet distributed its attention more broadly across the ECG segment than the baseline BLSTM model, consistent with its design goal of leveraging segment-level context. The authors are careful to note that these analyses are descriptive rather than proof of physiological causation, and they acknowledge limitations, including the use of a single lead, a predefined external subset, and the need for prior knowledge of beat locations.

Even so, the study offers a compelling template for how modest, well-targeted architectural changes can yield outsized gains in clinical AI. By feeding the big picture back into the fine details before the final vote, GCTRNet shows that the way a network organizes its own internal representations matters as much as the raw computing power it wields. As wearable ECG devices continue to flood clinics and consumer pockets with data, approaches that squeeze more diagnostic insight from every precious second of signal may prove decisive in turning arrhythmia screening from an art into an automated science.

Subject of Research: Cardiology AI

Article Title: GCTRNet: global context-gated temporal refinement for short-window ECG-based premature ventricular contraction detection

Article References: Shi, M., Yang, Y., & Chen, J. (2026). GCTRNet: global context-gated temporal refinement for short-window ECG-based premature ventricular contraction detection. Frontiers in Physiology, 17, Article 1979923. https://doi.org/10.3389/fphys.2026.1979923

Image Credits: AI Generated

DOI: 10.3389/fphys.2026.1979923

Keywords: ECG, premature ventricular contractions, deep learning, BLSTM, arrhythmia detection, GCTRNet, cardiology, machine learning, global, context-gated, temporal, refinement

At its core, a digital twin is a continuously updated simulation model that learns over time. Unlike conventional computational models, digital twins represent dynamical systems that can model both populations and individuals, integrating longitudinal data, physiological measurements, and clinical information to simulate real-world health processes. Many are built on mechanistic models that can even provide causal information among system variables, which means they offer explainable models allowing not only to make predictions but leading to structural interpretations. That combination of prediction and explanation is what distinguishes a true digital twin from an ordinary model, and it is why the concept, which first gained traction in engineering and manufacturing around the year 2000, is now being translated into medicine with such urgency.

To gauge how quickly the field is moving, the authors searched the Dimensions database of abstracts and citations for the term digital twin in titles and abstracts. The search yielded 5,641 articles in total, including 2,908 identified from titles alone, distributed across 21 categories of the Health Research Classification System developed by the UK Clinical Research Collaboration Partners. Most articles fall within the broad category generic health relevance, with 4,367 publications and 57,828 citations, followed by cardiovascular with 529 publications and cancer with 322. The timeline of published articles in the top five categories from 2017 to 2025 reveals a striking pattern: while the general relevance of digital twins in medicine became apparent in 2019 within the generic health relevance category, uptake in all other categories did not occur until 2023. The authors note that this delay is understandable, given the challenges of translating the digital twin concept from engineering to medical applications.

The bibliometric analysis also reveals which research fields have contributed to this development. Among all HRCS categories, Information and Computing Sciences dominates all other research fields followed by Engineering. Interestingly, while the Manufacturing Engineering field contributes a substantial number of publications across all HRCS categories, the majority are concentrated in generic health relevance, suggesting a strong foundational focus with potential for further expansion into more specialized medical applications. When the authors looked at Clinical Sciences, the most widely studied medical areas were cardiovascular, metabolic and endocrine, and cancer. Smaller categories tell their own stories: when including categories with fewer publications, renal and urogenital shows the highest citation impact across all fields with an average of 28.80 citations per article, while the inflammatory and immune system and respiratory categories also exhibit relatively high citation averages, indicating elevated interest in these areas.

Some of the most compelling proofs of concept lie outside the individual patient altogether. One study applied a simulation-based digital twin of emergency medical communication centers to evaluate organizational changes on accessibility. The digital twin models emergency call center operations under decompartmentalized scenarios, showing that more flexible call distribution improves service quality. A related study demonstrated the use of digital twins combined with discrete event simulation to optimize workflows in critical care units, employing a novel dual-layer architecture that tracks both physical and conceptual entities in real time, with cloud-based monitoring of staff-performed tasks from observation forms. These results demonstrate how digital twins can provide an objective, data-driven tool to optimize emergency response systems, enhance patient safety, operational efficiency, and precision care by aligning actual clinical practice with ideal workflows.

Digital twin models of the human heart are among the most widely studied, and the technical sophistication of these systems is remarkable. One team presented a multi-scale electro-mechanical whole heart model that includes a coupled description of electrophysiology, mechanics, and a closed-loop model of circulation. This model allows the description of membrane kinetics, excitation-contraction coupling and active tension generation in the atria and the ventricles, and it can be personalized by adjusting characteristics such as active tension or conduction velocity. To tame the enormous computational cost of such high-fidelity simulations, researchers introduced a surrogate model for cardiac digital twins based on Latent Neural Ordinary Differential Equations. The model learns pressure-volume dynamics from high-fidelity simulations while reducing computational complexity, enabling fast analyses such as sensitivity studies and parameter estimation with uncertainty quantification, and thereby significantly lowering the computational barrier for cardiac digital twins.

Oncology is the second most widely studied disease category for digital twin applications, and two recent examples illustrate the breadth of the approach. Researchers developed a quantitative systems pharmacology-based digital twin framework for TCR-engineered T cell therapy in patients with solid tumors, including metastatic HPV-associated epithelial cancers and pancreatic cancer. These digital twins capture the kinetics of infused and endogenous T cells across blood, lymph nodes, tumor, and peripheral tissues. Patient-matched digital twins reproduce observed T cell dynamics and show that stem cell-like memory T cells are key determinants of expansion and persistence, explaining inter-patient variability. In silico simulations suggest that enriching these stem cell-like memory T cells enhances persistence and enables lower dosing, providing a quantitative tool to optimize T cell therapies. Separately, another team introduced a model to predict treatment-induced toxicity in patients with acute myeloid leukemia, employing a mechanistic model of venetoclax and azacitidine therapy informed by measurements of neutrophil counts and blast percentages from blood samples. This study demonstrated that continuously updating the digital twin with new data enhances its predictive performance over time.

Mental health is emerging as a surprising frontier for digital twin technology, with three distinct systems already demonstrating what is possible. One team proposed a digital twin-based framework implemented as a chatbot system that analyzes the mental status of individuals and provides personalized feedback based on the severity of their condition. The system leverages pre-trained BERT models fine-tuned on the E-DAIC dataset to detect varying severity levels, achieving high accuracy and usability. By creating virtual representations of mental states, this approach addresses barriers such as stigma, limited accessibility, and cost, enabling scalable screening and early intervention. A similar concept, a digital twin-inspired mental health monitoring system called MTWIN, creates a virtual representation of a patient’s psychological state by integrating personal and medical information, wearable sensor data, environmental factors, and emotion predictions from a machine learning model. Finally, the Digital Alzheimer’s Disease Diagnosis model uses personalized biomarkers derived from non-invasive EEG recordings to reconstruct patient-specific neurodegeneration, capturing synaptic and connectivity decline. The model predicts cerebrospinal fluid biomarker positivity and clinical conversions with high accuracy, outperforming standard EEG methods and demonstrating the potential of digital twins to transform early diagnosis in Alzheimer’s disease.

Despite these promising capabilities, the authors are candid about the challenges that must be addressed before medical digital twins become applicable for widespread clinical use. Limited access to high-quality, longitudinal, and multimodal patient data is a major obstacle, as digital twins are largely data-driven and repeated measurements over time are required to establish models that can be personalized to individual patients, though data from wearables may provide valuable complementary information alongside clinical and genomic sources. Ensuring the accuracy and robustness of digital twins remains a major barrier to clinical adoption and requires rigorous, task-specific validation against conventional approaches, with standardized benchmarks still an open challenge spanning data quality, model validation, clinical utility, interoperability, and uncertainty quantification. Computational complexity poses another hurdle: high-resolution multimodal data, physics-informed neural networks, and high-fidelity organ-level simulations are computationally intensive and require large-scale computing resources, making real-time model updating challenging, though hybrid physics-machine learning surrogate models and edge-optimized architectures can reduce latency. Regulatory issues represent a further major challenge, as existing frameworks are not yet fully adapted to dynamic, data-driven models that are continuously updated with new patient data, and questions around data privacy, ownership, and informed consent must be addressed.

Looking ahead, the survey identifies several promising yet demanding directions for future research. Slowly progressing diseases may be especially well suited for digital twins, since Alzheimer’s disease and Parkinson’s disease involve gradual changes over many years, making them ideal for longitudinal modeling and long-term data integration, with wearable sensor data capturing subtle disease-induced changes. Rather than creating separate disease-specific digital twins, integrating electronic health records allows the construction of a comprehensive digital twin representing the underlying patient, capturing the interactions and progression of multiple coexisting conditions. The concept extends beyond individual patients to entire health systems: public health systems may be represented by digital twins that model expenditures across diseases, resource allocation, and patient care pathways, simulating the impact of policy changes, new interventions, or demographic shifts on healthcare costs and outcomes. And just as industrial digital twins leverage interoperability for efficiency and scalability, medical digital twins may benefit from connected frameworks in which multiple specialized twins, such as heart, liver, metabolism, and mental health, share data, models, and simulations to address complex multi-factorial conditions. Medical digital twins, the authors conclude, are an emerging paradigm with the potential to profoundly transform medicine due to their ability to adapt to a wide range of problems.

Subject of Research: Digital twins in medicine

Article Title: Mapping the future of medicine through digital twins

Article References: Emmert-Streib, F., Tripathi, S., & Yli-Harja, O. (2026). Mapping the future of medicine through digital twins. Frontiers in Molecular Medicine, 6, Article 1840371. https://doi.org/10.3389/fmmed.2026.1840371

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1840371

Keywords: digital twins, medicine, cardiology, oncology, mental health, health systems, machine learning, personalized medicine, wearables, Alzheimer's disease, data integration, clinical validation

The trial, led by Danish researchers including Henning Bundgaard, tested a radical idea: rather than committing to a fixed duration of antibiotic therapy, clinicians would stop treatment once patients met predefined criteria for clinical stability. The results showed that this response-tailored strategy successfully shortened the overall treatment duration without increasing the risk of death or the need for cardiac surgery. However, the approach came with a notable trade-off: rates of relapse of endocarditis or bacteraemia were tripled compared with standard-duration therapy.

Infective endocarditis remains a formidable clinical challenge. The infection destroys valve tissue, can seed emboli throughout the body, and carries substantial mortality even with modern care. Standard guidelines, including the 2023 European Society of Cardiology recommendations, have long endorsed prolonged antibiotic courses — typically four weeks for many cases and six weeks for more complex infections — on the assumption that complete eradication of bacteria from vegetations requires sustained drug exposure.

The original POET trial, published in 2019, had already challenged one pillar of conventional treatment by showing that switching stable patients from intravenous to oral antibiotics partway through their course was non-inferior to continued intravenous therapy. That finding, later reinforced by the Danish POETry implementation study, reshaped practice in many centers and reduced the burden of prolonged central venous catheter use. POET II now pushes the logic one step further by questioning the total duration itself.

In the response-tailored arm of POET II, antibiotics were discontinued once patients achieved clinical stability — defined by criteria such as absence of fever, hemodynamic stability, and lack of ongoing bacteremia — rather than after a predetermined number of weeks. The trial’s rationale, outlined in its design publication, was that a subset of patients may clear their infection adequately with shorter exposure, and that continuing antibiotics in these individuals offers little added benefit while exposing them to catheter complications, adverse drug effects, and antimicrobial resistance pressures.

The tripling of relapse rates is the trial’s central caution. Relapse in endocarditis — distinguished from reinfection by the recurrence of the same microorganism, typically within weeks to months of treatment completion — signals that bacteria persisted within the vegetation despite therapy. In a commentary accompanying the trial, Mary Philip and Gilbert Habib of La Timone Hospital in Marseille emphasize that the safety of the response-guided strategy will depend fundamentally on rigorous patient selection and close multidisciplinary follow-up.

The distinction between relapse and reinfection carries practical weight. Relapse typically involves the same organism and suggests inadequate eradication, whereas reinfection involves a new episode with a different microorganism. The tripling observed in POET II suggests that, for some patients, stopping antibiotics at the point of clinical stability leaves residual bacteria capable of re-emerging. Identifying which patients harbor such residual infection — and which have truly cleared it — is the core challenge for tailored therapy.

Philip and Habib frame POET II as a genuine conceptual advance beyond the oral-switch paradigm of the original POET trial. Where POET changed the route of delivery without altering total exposure, POET II directly tests whether total exposure can be reduced. The commentary authors suggest that the era of one-size-fits-all duration may be giving way to individualized approaches, in which the intensity and length of therapy are calibrated to each patient’s clinical trajectory, microbiological profile, and response to initial treatment.

The implications for clinical practice are likely to be gradual rather than immediate. Guidelines will need to weigh the benefit of shorter treatment — fewer catheter days, lower drug toxicity, reduced selection pressure for resistance, and shorter hospital stays — against the increased relapse risk. Patient selection will be paramount: individuals with virulent organisms, large vegetations, prosthetic material, or complicated courses may remain poor candidates for early cessation, while stable patients with uncomplicated disease and sensitive organisms may benefit most.

Close follow-up will be equally critical. Patients treated with a response-tailored strategy will require vigilant monitoring for early signs of relapse, including recurrent fever, new bacteremia, or hemodynamic deterioration, with ready access to repeat imaging and blood cultures. Multidisciplinary teams — cardiologists, infectious disease specialists, cardiac surgeons, and microbiologists — will need coordinated protocols to detect and manage relapse promptly. As Philip and Habib conclude, POET II marks a genuine shift in thinking, but its safe adoption will depend on the discipline of its implementation: the right patients, the right criteria, and the right follow-up.

Subject of Research: Infective Endocarditis

Article Title: Duration of antibiotic treatment for infective endocarditis: should we move towards tailored therapy?

Article References: Philip, M., & Habib, G. (2026). Duration of antibiotic treatment for infective endocarditis: should we move towards tailored therapy?. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-026-01360-1

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01360-1

Keywords: infective endocarditis, antibiotics, POET II trial, tailored therapy, cardiology, infectious diseases, Duration, antibiotic, treatment, infective, endocarditis, should

The research, published in Frontiers in Global Women’s Health, synthesizes findings from the HeartGap project, a health services research initiative funded by the German Innovation Fund of the Federal Joint Committee. It is an exploratory mixed-methods study that combined a scoping review of 117 articles with qualitative focus groups involving 41 physicians and 46 nurses, and nationwide surveys of 155 physicians, 111 nurses, and 390 cardiology inpatients. Gender sensitivity among healthcare professionals was measured using the validated Nijmegen Gender Awareness in Medicine Scale, or N-GAMS, while perceived implementation of gender-sensitive personalized care, abbreviated GSC+, was assessed alongside guideline-derived knowledge items. Patient perspectives were analyzed descriptively and with multivariate linear regression models, weighted by hospital care level and region to reflect the German hospital landscape.

The numbers reveal a paradox that the authors describe as a disconnect between attitudes and practice. Physicians scored highest on gender sensitivity, with a mean of 3.95 on the N-GAMS scale, compared with 3.46 among nurses. Yet when asked how extensively gender-sensitive care was actually implemented on their wards, physicians gave the most critical assessment, rating it at just 2.45 on a four-point scale. Nurses rated implementation at 2.91, and patients, remarkably, gave the most positive evaluation of all at 3.04. The group difference was statistically significant, and post-hoc analyses using Tukey’s HSD test confirmed that physicians differed significantly from both nurses and patients, while nurses and patients agreed closely with each other. In other words, the professionals with the greatest awareness of sex and gender differences in cardiovascular medicine were the least convinced that this awareness was translating into everyday care.

Higher gender sensitivity did not correspond with higher perceived implementation, a finding that held across the study components. Physicians demonstrated moderate to high guideline-based knowledge, correctly answering on average 63 percent of knowledge items on sex- and gender-specific aspects of cardiovascular guidelines. But item-level analysis exposed gaps precisely where clinical decisions hinge: sex-specific diagnostic thresholds and pharmacological differences. Multivariate analyses showed that working in a university hospital was associated with higher knowledge, yet no significant association emerged between gender sensitivity, knowledge, and perceived implementation. Awareness, it seems, is a necessary but insufficient condition for change.

The qualitative focus groups fleshed out why this gap persists. Physicians framed gender-sensitive care primarily in biomedical terms, associating it with sex-specific differences in disease prevalence, symptom presentation, and drug response. Atypical symptom presentation in women with acute coronary syndrome was the most frequently cited example. Social and communicative dimensions, such as interaction patterns, unconscious bias, or gendered expectations in clinical encounters, were mentioned less consistently and were not systematically integrated into clinical reasoning. Nurses, by contrast, described a practice-oriented and relational understanding of gender-sensitive care, encompassing communication, protection of privacy, same-sex care during intimate procedures, and sensitivity to emotional and psychosocial needs, along with intersecting factors like age, cultural background, religion, and language. Both groups reported that gender-sensitive differentiation was rarely formalized in institutional standards, documentation systems, or standard operating procedures, and was instead enacted intuitively, based on individual experience and situational discretion.

Structural barriers dominated the barrier analysis across all methods. Time pressure, staff shortages, high workload, and economic constraints were named repeatedly by physicians and nurses alike as the principal obstacles to consistent gender-sensitive care. The scoping review, which screened 23,508 articles and included 117 in content analysis, organized implementation measures into four interdependent dimensions: politics, research and science, education, and institutions of care. It found that political commitment, mandatory gender criteria in research funding, curricular integration, and organizational measures such as quality circles and diversity officers all facilitate implementation, while missing binding regulations, underrepresentation of women and gender-diverse populations in clinical studies, limited curricular space, and insufficient institutional accountability continue to hinder it. Sustainable implementation, the review concluded, depends on an overarching strategy linking all four dimensions rather than relying on individual commitment alone.

The patient survey adds a layer of nuance that complicates the picture. Of the 390 inpatients surveyed across 14 hospitals in six German federal states, 44.2 percent were women and the average age was 71.1 years. Patients evaluated gender-sensitive care positively and reported comparatively low additional needs. Same-sex nursing care, for instance, was rated as relatively unimportant on average, though women desired it significantly more than men. Women were also more satisfied with the trust and confidentiality of medical consultations. Regression analyses revealed that patients born in Germany reported a significantly lower need for gender-sensitive care than patients born elsewhere, and women reported a greater need than men, though the sociodemographic variables explained only 5 percent of the variance. The authors propose an expectation paradox: patients may evaluate visible and experiential aspects of care, such as trust, communication quality, and perceived attentiveness, while the biomedical, diagnostic, and structural components of gender-sensitive differentiation remain largely invisible to them. Implicit norms of equal treatment may further reinforce this pattern, since equal treatment is often perceived as fair even when relevant differences are not actively addressed.

Self-reported awareness of sex-related cardiovascular differences was unevenly distributed. Slightly more respondents, 62 percent, were aware that heart attack symptoms can differ between women and men, compared with 51 percent who knew that normal blood pressure values differ by sex. Women reported significantly greater awareness of myocardial infarction symptom differences than men, and 47 percent of respondents had encountered information about gender-sensitive care through television, radio, or magazines. Higher awareness was also associated with higher levels of school education. The authors caution that these items measured perceived awareness rather than objective cardiovascular knowledge, and that the accompanied survey format, in which researchers read questions aloud to inpatients recovering from cardiac events, may have encouraged socially desirable responses.

The study’s limitations are acknowledged candidly. The patient questionnaire used a single German-language item for sex and gender and did not separately assess sex assigned at birth and current gender identity, so the quantitative comparisons are restricted to women and men and cannot be generalized to gender-diverse populations. The survey period was extended due to recruitment difficulties, and the low internal reliability of the six-item needs index, with a Cronbach’s alpha of 0.512, means results involving it should be interpreted with caution in this exploratory context. The study also focused exclusively on inpatient cardiology; in specialties characterized by more intimate or long-term care relationships, such as gynecology, urology, or psychiatry, other dimensions of gender-sensitive care, including same-sex care and experiences of shame, may be perceived as more relevant and evaluated differently.

The central conclusion is unambiguous: organizational, structural, and systemic barriers, rather than negative attitudes or lack of awareness, are the relevant factors associated with implementation gaps in gender-sensitive cardiology care. The authors, an interdisciplinary team from Hannover Medical School, Figus Research Institute, the Institute for Gender Health, and University Hospital Magdeburg, distilled five recommendations for action with the help of a six-member expert advisory council. They call for strengthening the evidence base on sex- and gender-specific differences, systematically integrating gender sensitivity into clinical guidelines and nursing expert standards in visible and operational form, raising awareness among both the population and healthcare professionals, utilizing organizational structures such as documentation systems and quality management to embed gender-sensitive care into routines, and integrating gender-sensitive and intersectional perspectives into education and training across all healthcare professions. In cardiology, where sex and gender affect symptom recognition, diagnostic pathways, therapeutic decisions, and outcomes, insufficient implementation may have consequences that extend beyond fairness to directly impact care quality and patient safety. Gender-sensitive personalized care, the study argues, is not an optional supplement but a core element of quality, equity, and patient safety, and closing the gap between awareness and practice will require structural anchoring across research, education, policy, and healthcare organizations rather than individual initiative alone.

Subject of Research: Health

Article Title: Gender sensitivity and its implementation in inpatient cardiology: a mixed-methods study of patient and healthcare professional perspectives

Article References: Sgraja, S., Mollenhauer, J., Kloepfer, M., Seeland, U., Kurscheid, C., & Amelung, V. E. (2026). Gender sensitivity and its implementation in inpatient cardiology: a mixed-methods study of patient and healthcare professional perspectives. Frontiers in Global Women's Health, 7, Article 1871546. https://doi.org/10.3389/fgwh.2026.1871546

Image Credits: AI Generated

DOI: 10.3389/fgwh.2026.1871546

Keywords: gender medicine, cardiology, health equity, implementation science, patient-centered care, Gender, sensitivity, implementation, inpatient, mixed-methods, patient, healthcare

The research team, led by investigators from Hospital Clinic de Barcelona, Klinicki bolnicki centar Zagreb, IDIBAPS and ICREA, analyzed 511 subjects: 286 endurance athletes training more than three hours per week for at least five years, and 225 patients with established systemic arterial hypertension treated with at least one antihypertensive drug for at least three years. Each participant underwent a detailed cardiovascular risk assessment, followed by two-dimensional and three-dimensional echocardiography with speckle-tracking strain analysis, and a peripheral venous blood sample drawn during the same clinical visit. The imaging protocol followed society recommendations for chamber quantification, and three-dimensional left atrial volumes were analyzed in 84 percent of the cohort using dedicated quantification software.

The biomarker panel was deliberately broad, spanning three biological domains relevant to atrial pathology. Markers of myocardial damage included brain natriuretic peptide, troponin I, oncostatin M, heart-type fatty acid-binding protein and placenta growth factor. Vascular endothelial dysfunction was assessed through endothelial cell-specific molecule 1, also known as endocan-1. Fibrosis was probed with matrix metalloproteinases 1, 2 and 9, the chemokines CXCL6 and CXCL16, and galectin-3, a beta-galactoside-binding lectin that mediates profibrotic pathways. The investigators then fitted univariable and multivariable linear regression models, using stepwise backward selection, to determine which patient characteristics and echocardiographic measures of left ventricular and left atrial size and function predicted each biomarker level.

The first striking finding concerns what did not differ between the groups. Markers of myocardial damage, including BNP and troponin I, occupied a narrow range of values in this relatively healthy cohort, reflecting the low prevalence of heart failure and acute myocardial injury among the participants. Oncostatin M and heart-type fatty acid-binding protein showed wider distributions but no statistically significant difference between athletes and hypertensive patients. Placenta growth factor, although similarly narrow in range, was significantly lower in athletes than in hypertensive patients, while endocan-1, the endothelial dysfunction marker, was significantly higher in the athlete group.

In contrast, the fibrosis biomarkers told a more consistent story. CXCL6, CXCL16, MMP-1, MMP-9 and galectin-3 were all uniformly elevated in the hypertensive cohort compared with the endurance athletes. Median galectin-3 levels, for instance, stood at 7.5 nanograms per milliliter in hypertensive patients versus 6.8 in athletes, a statistically significant difference. Median MMP-9 concentrations were also markedly higher in the hypertension group. These elevations align with the known biology of pressure-overload atrial remodeling, in which chronic stretch activates fibroblasts and drives extracellular matrix turnover in the atrial wall.

The regression analysis revealed that biomarker levels are far from pure readouts of atrial pathology. Age, gender, body mass index, body surface area and renal function all exerted significant influence on circulating concentrations. Only heart-type fatty acid-binding protein showed a weak correlation with impaired renal function, and the estimated glomerular filtration rate, although statistically lower in hypertensive patients, was not clinically different between groups. The authors caution that biomarker levels are shaped by renal clearance, hepatic metabolism, inflammation and other systemic factors unrelated to atrial remodeling, which complicates any direct comparison between patient groups.

Within the hypertensive cohort, several specific associations emerged. Dyslipidemia predicted BNP and troponin levels. Oncostatin M related to smoking status, left ventricular dimensions and left atrial active emptying fraction. Placenta growth factor associated with body mass index. MMP-1 levels were predicted by body surface area, left ventricular longitudinal function and left atrial active emptying fraction, while MMP-9 related to blood pressure, body surface area and left atrial contractile function. CXCL6 associated with gender and left atrial maximal volume. Notably, patients on ACE inhibitors showed slightly lower CXCL16 levels, whereas biomarker levels did not differ based on angiotensin II receptor blocker use.

In the athlete cohort, the picture was different. Troponin levels related to left ventricular ejection fraction, average mitral annular velocity and left atrial active emptying fraction. Placenta growth factor associated with left ventricular mass index and left atrial active emptying fraction. MMP-2 levels were predicted by weekly training volume measured in metabolic equivalent minutes. Endocan-1 related to body mass index, basal septal thickness and left atrial maximal volume. Galectin-3, in athletes, associated only with body mass index rather than any atrial functional measure.

The headline result concerns galectin-3 in hypertension. In the multivariable regression model, galectin-3 was independently associated with left atrial reservoir strain, with a Pearson correlation of minus 0.286 and a standardized beta of minus 0.254 at a p-value of 0.007. Crucially, this association was not confounded by patient characteristics such as gender, body mass index or body surface area that would otherwise complicate interpretation. Left atrial reservoir strain, measured by speckle-tracking echocardiography, captures the atrium’s ability to expand during ventricular systole and is considered a sensitive marker of atrial cardiopathy. The finding suggests that in hypertensive patients, circulating galectin-3 may serve as a molecular counterpart to this imaging parameter.

The authors are careful about the limits of their work. Fibrosis biomarkers are not cardiac-specific but reflect systemic collagen turnover, and because the left atrium has relatively low tissue mass, even significant atrial fibrosis may only marginally affect total circulating concentrations. Larger organs such as the liver correlate better with blood biomarkers due to their greater organ mass. Moreover, circulating biomarkers reflect active fibrogenesis and fibrolysis, whereas imaging captures both long-term structural remodeling and acute changes in loading conditions. The study lacked a matched control group, and underlying age and sex differences between the two cohorts limit direct comparison, although the authors argue these differences reflect real-world population characteristics and should not bias within-group analyses. Corrections for multiple comparisons were not performed, increasing the risk of false positive findings.

Overall, the weak correlation between circulating and imaging biomarkers underscores their complementary rather than interchangeable nature. The modest relationship between galectin-3 and left atrial reservoir strain highlights the limitations of using galectin-3 alone as a strong predictor of atrial fibrosis and remodeling. The authors suggest that prospective follow-up of this cohort, identifying individuals who develop atrial fibrillation, could confirm whether biomarker levels serve as an additional complementary screening marker of atrial cardiopathy and arrhythmia risk. Until then, galectin-3 stands as a promising but unproven molecular companion to the echocardiographic evaluation of atrial health in hypertension, with clinical follow-up needed to relate these findings to outcomes.

Subject of Research: Blood biomarkers of left atrial remodeling in people at risk of atrial fibrillation

Article Title: Blood biomarkers and atrial remodeling in patients at risk of atrial fibrillation

Article References: Loncaric, F., Forado Benatar, I., Mimbrero Guillamon, M., Nunno, L., Jimenez-Arjona, R., Tirapu, L., Montserrat, S., Sanchis, L., Doltra, A., Bijnens, B., & Sitges, M. (2026). Blood biomarkers and atrial remodeling in patients at risk of atrial fibrillation. Frontiers in Molecular Medicine, 6, Article 1801523. https://doi.org/10.3389/fmmed.2026.1801523

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1801523

Keywords: atrial fibrillation, left atrial remodeling, galectin-3, biomarkers, arterial hypertension, endurance athletes, echocardiography, speckle-tracking strain, fibrosis, cardiology, molecular medicine, preventive cardiology

The condition in question is coronary microvascular dysfunction, or CMD, a disorder of the tiny arteries and arterioles that branch off the main coronary arteries. While major coronary blockages are easy to spot on an angiogram, the microvasculature operates at a scale beyond direct imaging. When these small vessels fail to dilate properly, the heart muscle cannot increase its blood supply during stress, even when the large arteries look clean. In aortic stenosis, the thickened heart muscle wall demands more oxygen while the high pressure inside the heart chamber compresses the microcirculation, creating a perfect storm for microvascular impairment.

A team of researchers from Thailand, led by Maethas Panyawongkhanti and colleagues, systematically searched five databases for studies published between January 2010 and December 2025 that assessed CMD in adults with severe aortic stenosis undergoing TAVI. The team accepted only rigorous measurement techniques: wire-based thermodilution, which threads a pressure-temperature sensor into the coronary artery; angiography-derived indices calculated from routine catheterization images; Doppler ultrasound measurements of coronary flow; and stress cardiac magnetic resonance imaging. The protocol was prospectively registered and the analysis followed PRISMA 2020 reporting standards, with study quality graded using the Newcastle-Ottawa Scale and the certainty of evidence evaluated under the GRADE framework.

Eleven primary studies made the final cut. Ten of them, encompassing 1,212 patients, contributed to the prevalence analyses, while an additional study of 126 patients entered only the sensitivity analyses. The headline finding was striking: the pooled prevalence of CMD before TAVI was 46.8 percent. But that number came with a caveat that turned out to be the study’s most important message. When CMD was measured with wire-based thermodilution, the gold standard involving direct intracoronary sensors, prevalence was 46.8 percent across six studies and 324 patients. When angiography-derived indices were used instead, across four studies and 888 patients, prevalence dropped to 38.4 percent, with essentially no statistical heterogeneity between those studies.

The discrepancy between modalities is not merely academic. Wire-based thermodilution measures the minimal microvascular resistance directly, an absolute physiological quantity expressed in units of pressure times time divided by flow. Angiographic indices, by contrast, are relative ratios that compare resting and hyperemic states and can be influenced by factors such as resting flow velocity, heart rate, and the pressure gradient across the stenotic valve itself. Because the two approaches define CMD differently, they cannot be assumed to identify the same patients. The high heterogeneity statistic of 72 percent in the thermodilution group reflected non-equivalent CMD definitions across studies, meaning that the pooled figure should be interpreted as a range rather than a precise point estimate.

The researchers also tracked what happens to the microcirculation after the valve is replaced. Coronary flow reserve, or CFR, the ratio of hyperemic to resting coronary blood flow, increased after TAVI by a pooled mean difference of 0.49, with a 95 percent confidence interval of 0.27 to 0.71, across five studies and 103 paired observations. On the surface, this looks like good news: the microvasculature appears to recover once the valve obstruction is gone. But the authors caution that the improvement may be deceptive. CFR is a ratio, and when resting blood flow demand falls after valve replacement, the denominator of the ratio shrinks, mechanically inflating the reserve even if the absolute capacity of the microcirculation is unchanged.

The narrative synthesis of microvascular resistance data supported exactly that interpretation. Reductions in microvascular resistance were confined to pressure-to-velocity and reserve ratio indices, which are relative measures sensitive to changes in resting conditions. In contrast, absolute minimal microvascular resistance, the most direct measure of the microcirculation’s structural capacity, showed no significant change after TAVI across four studies and 85 patients. In other words, the heart’s resting oxygen demand drops after valve replacement, which makes the reserve ratios look better, but the underlying architecture of the microvasculature may remain impaired. This distinction matters because structural microvascular damage, such as fibrosis and capillary rarefaction in the chronically hypertrophied heart muscle, is unlikely to reverse simply by removing the valve obstruction.

The prognostic question, whether CMD before TAVI predicts major adverse cardiovascular events, or MACE, after the procedure, yielded a hypothesis-generating rather than definitive answer. Across two studies and 585 patients, the hazard ratio for MACE associated with baseline CMD was 3.22, with a 95 percent confidence interval of 0.98 to 10.60 and substantial heterogeneity of 78 percent. The confidence interval crosses unity, meaning the association is not statistically significant at the conventional threshold, and the wide range reflects the small number of contributing studies and the incompatible hazard ratio calculations used in the original research. The authors explicitly state that the CMD-MACE association should be viewed as hypothesis-generating due to limited studies, varied CMD definitions, and incompatible statistical approaches.

What emerges from this review is a nuanced picture of a common but underrecognized complication. Coronary microvascular dysfunction affects a substantial proportion, plausibly between one-third and one-half, of patients with severe aortic stenosis before valve replacement, and the diagnostic method fundamentally shapes the estimated burden. TAVI improves coronary flow reserve, but likely by reducing resting demand rather than by repairing the microcirculation itself. Whether CMD independently predicts poor outcomes after TAVI remains an open question that the current evidence cannot settle.

The authors call for prospective multicenter studies with standardized CMD definitions to resolve these uncertainties. Such studies would need to agree on diagnostic thresholds, follow patients over meaningful time horizons, and use compatible statistical methods for prognostic modeling. Until then, the message for clinicians is clear: a successful valve replacement does not guarantee a fully healthy microcirculation, and the tools used to assess it are not interchangeable. For the growing population of elderly patients undergoing TAVI worldwide, the microscopic vessels of the heart may represent the next frontier in structural heart disease care.

Subject of Research: Coronary microvascular dysfunction prevalence, post-TAVI coronary flow reserve changes, and prognostic significance in severe aortic stenosis patients undergoing transcatheter aortic valve implantation

Article Title: Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation: A systematic review and meta-analysis

Article References: Panyawongkhanti, M., Chintrakulchai, P., Tanking, C., & Luangphiphat, W. (2026). Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation: A systematic review and meta-analysis. PLOS One, 21(10), e0360374. https://doi.org/10.1371/journal.pone.0360374

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360374

Keywords: coronary microvascular dysfunction, TAVI, aortic stenosis, coronary flow reserve, meta-analysis, PLOS One, cardiology, heart disease, Coronary, microvascular, dysfunction, patients

Lithium has been a mainstay of bipolar disorder treatment since the mid-twentieth century, prized for its mood-stabilizing properties. But the drug operates on a razor’s edge. Its therapeutic window is narrow, meaning the difference between an effective dose and a toxic one is small. When serum concentrations climb above 1.5 milliequivalents per liter, patients risk multiorgan dysfunction affecting the nervous system, kidneys, gastrointestinal tract, endocrine system, and, less commonly, the cardiovascular system. Cardiac complications, while infrequent, can include sinoatrial node dysfunction, atrioventricular block, and dangerous ventricular arrhythmias, with bradycardia, an abnormally slow heart rate, often serving as the first visible warning sign.

In this case, the patient had been living with bipolar I disorder and had been taking lithium under regular monitoring by her primary care physician. Her kidney function, tracked through creatinine levels, had been slowly deteriorating from 0.95 to 1.24 milligrams per deciliter over time, a red flag that would later prove consequential. Roughly a month before admission, she began experiencing progressively worsening tremors and myoclonic jerks, involuntary muscle twitches that were most noticeable during fine motor tasks like writing. Intermittent dizziness, lightheadedness, and mounting fatigue followed. Her family observed that she was drinking more water than usual and had episodes of slurred speech and altered mental status. Three days before hospitalization, she developed intermittent, bandlike pain in her right lower abdomen accompanied by loose stools and reduced oral intake.

On arrival, she was alert but showed signs of mild encephalopathy, a state of brain dysfunction. Her heart rate ranged between 30 and 49 beats per minute, dangerously slow for an adult. Abdominal examination revealed tenderness in the right lower quadrant without signs of peritoneal irritation, meaning the lining of the abdominal cavity had not yet become inflamed. Neurologically, she exhibited a resting tremor and occasional myoclonic jerks but no focal deficits, suggesting no localized brain lesion. Her mental status was slowed but she remained oriented to herself, her location, and the date.

Initial diagnostic workup painted a complex picture. An electrocardiogram revealed an idioventricular rhythm, a slow backup rhythm generated by the ventricles themselves, along with a left bundle branch block, a conduction abnormality. Laboratory results showed elevated creatinine at 1.43 milligrams per deciliter, non-anion gap metabolic acidosis, elevated white blood cell count, and hypernatremia at 149 millimoles per liter, indicating both kidney impairment and dehydration. Her serum lithium level measured 1.6 millimoles per liter, just above the toxic threshold. Abdominal X-rays showed severely distended bowel loops initially raising concern for small bowel obstruction, but a subsequent computed tomography scan of the abdomen and pelvis revealed the true culprit: an 8.6-centimeter distended cecum oriented transversely across the abdomen, consistent with cecal volvulus. A brain CT showed only chronic microvascular changes with no acute pathology, and a urinalysis positive for infection grew Streptococcus dysgalactiae on culture.

The clinical team synthesized these findings into a diagnosis of acute-on-chronic lithium toxicity complicated by cecal volvulus. Lithium was immediately discontinued, and aggressive intravenous hydration was initiated, later transitioning to 5 percent dextrose in water to address the hypernatremia. Nephrology specialists were consulted and recommended close monitoring of sodium and creatinine levels, along with the initiation of amiloride, a medication that addresses lithium-induced arginine vasopressin resistance, a condition in which the kidneys become inappropriately resistant to the hormone that regulates water balance. Cardiology advised against pacemaker placement, reasoning that the bradycardia was potentially reversible rather than stemming from permanent damage to the heart’s conduction system.

What followed was a diagnostic puzzle that unfolded over days. The patient’s lithium level steadily declined, reaching 0.1 millimoles per liter by hospital day 11, well within the normal range. Yet her encephalopathy and bradycardia persisted despite the falling drug concentration. This disconnect between serum levels and clinical symptoms proved to be the critical clue. The persistence of abdominal pain and worsening distension on repeat imaging prompted the surgical team to proceed with an exploratory laparotomy, during which they performed a right hemicolectomy, removing the affected portion of the colon, and an ileocolic anastomosis, reconnecting the small intestine to the remaining colon.

The outcome was dramatic. Following surgical correction of the bowel obstruction, the patient’s heart rate normalized and her neurological symptoms improved markedly. Postoperative ileus, a temporary paralysis of the intestines common after abdominal surgery, resolved with conservative management including intravenous hydration, antiemetics, and gradual reintroduction of a liquid diet. She was discharged in stable condition with resolved encephalopathy and a normal sinus rhythm at 79 beats per minute. The temporal relationship between surgical relief of the obstruction and the restoration of both cardiac and neurological function strongly suggested that the volvulus was not merely a coincidental finding but an active driver of her deterioration.

The authors propose a multifactorial mechanism to explain this clinical trajectory. First, the cecal volvulus impaired lithium clearance, likely by promoting dehydration and reducing renal perfusion, thereby allowing the drug to accumulate despite ongoing chronic therapy. Second, the abdominal distension caused by the twisted bowel likely triggered increased vagal tone, a reflexive activation of the parasympathetic nervous system that independently slows heart rate. This dual mechanism explains why the bradycardia persisted even as serum lithium levels fell: the mechanical obstruction continued to exert its vagal influence until it was physically corrected. The authors also hypothesize that lithium-associated gastrointestinal dysmotility may have predisposed the patient to the volvulus in the first place, creating a self-reinforcing cycle in which the drug slowed gut movement, the sluggish gut twisted and obstructed, and the obstruction further impaired drug elimination.

This case carries important lessons for clinicians managing patients on chronic lithium therapy. Serum lithium concentrations, while useful, may not accurately reflect the severity of toxicity in patients receiving long-term treatment, and clinically significant toxicity can occur despite levels that appear only modestly elevated. The authors emphasize that diagnosis should be guided by the overall clinical presentation rather than by laboratory values alone. They also highlight the value of sequential diagnostic reassessment: when symptoms persist or worsen despite appropriate treatment for an initial diagnosis, clinicians must remain open to additional contributing pathology. For patients with lithium toxicity who present with unexplained or refractory bradycardia, the authors recommend maintaining a high index of suspicion for structural gastrointestinal problems, as emergent surgical intervention may be required to break the cycle of drug accumulation and vagal-mediated cardiac slowing. The case ultimately underscores a broader principle in medicine: the body’s organ systems are deeply interconnected, and a problem in one system can cascade into unexpected and dangerous consequences elsewhere.

Subject of Research: Lithium toxicity and bradycardia caused by cecal volvulus-associated bowel obstruction

Article Title: Case Report: Lithium-induced bradycardia triggered by cecal volvulus: a case of obstruction-associated drug accumulation

Article References: Alnounou, A., Zou, H., Laird, M., Visak, C., Bilsland, S., Numbers, S., & Hughes, N. (2026). Case Report: Lithium-induced bradycardia triggered by cecal volvulus: a case of obstruction-associated drug accumulation. Frontiers in Gastroenterology, 5, Article 1728396. https://doi.org/10.3389/fgstr.2026.1728396

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1728396

Keywords: lithium toxicity, bradycardia, cecal volvulus, bowel obstruction, bipolar disorder, drug accumulation, vagal response, renal impairment, encephalopathy, case report, gastroenterology, cardiology